The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LH | +10.03% | +50.95% | +8.58% | +1,424% |
| S&P | +18.13% | +110.72% | +16.08% | +2,435% |
Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.
The company completed the spinoff of contract research organization Fortrea Holdings.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.56B | 8.6% |
| Gross Profit | $955.60M | 13.7% |
| Gross Margin | 26.82% | 1.2% |
| Market Cap | $23.85B | 27.1% |
| Market Cap / Employee | $0.34M | 0.0% |
| Employees | 70K | 4.5% |
| Net Income | $261.50M | 54.2% |
| EBITDA | $574.20M | 32.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $598.10M | -60.6% |
| Accounts Receivable | $2.27B | 1.8% |
| Inventory | 521.5 | 7.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.84B | -4.7% |
| Short Term Debt | $691.10M | -56.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.64% | 2.2% |
| Return On Invested Capital | 7.82% | -0.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $280.50M | 73.7% |
| Operating Free Cash Flow | $387.20M | 39.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 25.95 | 26.85 | 28.95 | 28.19 | -34.85% |
| Price to Book | 2.35 | 2.41 | 2.65 | 2.81 | 20.07% |
| Price to Sales | 1.48 | 1.49 | 1.63 | 1.75 | 17.64% |
| Price to Tangible Book Value | -10.36 | -10.75 | -13.74 | -15.13 | 24.94% |
| Price to Free Cash Flow TTM | 22.64 | 21.57 | 21.60 | 21.09 | -33.01% |
| Enterprise Value to EBITDA | 62.49 | 51.65 | 49.11 | 52.20 | -9.74% |
| Free Cash Flow Yield | 4.4% | 4.6% | 4.6% | 4.7% | 49.29% |
| Return on Equity | 9.4% | 9.0% | 9.3% | 10.1% | 86.78% |
| Total Debt | $7.27B | $6.52B | $6.55B | $6.53B | -15.41% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
